A Phase 3 interventional study of Donanemab and Placebo in Alzheimer Disease, sponsored by Eli Lilly and Company. Recruiting at 30 sites in China. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
The main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD).
The study drug will be administered intravenously (IV) (into a vein in the arm).
The study will last up to approximately 156 weeks, excluding screening.
3,678 studies on the registry are indexed under Alzheimer Disease; 872 are open to participants now.
This study's planned enrollment of 140 is above the median of 70 across 2,808 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.
Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
A reliable study partner who:
Exclusion Criteria:
Donanemab administered intravenously (IV)
Drug: Donanemab
Placebo administered IV
Drug: Placebo
Administered IV
Also known as: LY3002813
Administered IV
Time to Clinical Progression as Measured by Clinical Dementia Rating-Global Score (CDR-GS)
Time frame: Baseline Up to Week 156
Change From Baseline in Plasma Phosphorylated Tau at Threonine 217 (P-tau217)
Time frame: Baseline, Week 52
Change From Baseline as Measured by Clinical Dementia Rating-Sum of Boxes (CDR-SB)
Time frame: Baseline Up to Week 156
Pharmacokinetics (PK): Peak Concentrations of Serum Donanemab
Time frame: Baseline Up to Week 156
PK: Trough Concentrations of Serum Donanemab
Time frame: Baseline Up to Week 156
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Sap, Csr
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company